Skip to main content

Table 2 Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival and Time-to-Progression of Disease

From: Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization

Prognostic Factor Parameters Compared Overall Survival (OS) Time to Progression (TTP)
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age >65 vs. ≤65 years 1.13 (0.44–2.94) 0.12 N/A 1.14 (0.44–2.95) 0.80 N/A
Gender Male vs. Female 1.28 (0.41–3.98) 0.67 N/A 1.19 (0.39–3.66) 0.76 N/A
Comorbidity Present vs. Absent 0.80 (0.26–2.45) 0.69 N/A 0.98 (0.32–3.00) 0.97 N/A
Portal Vein Thrombosis Main vs. Branch Portal Vein 1.70 (0.55–5.25) 0.36 N/A 1.68 (0.55–5.17) 0.37 N/A
Occlusive vs. non-occlusive 1.23 (0.39–3.82) 0.72 N/A 1.19 (0.39–3.66) 0.76 N/A
Tumor Size >10 vs. ≤10 cm 1.02 (0.39–2.65) 0.97 N/A 0.89 (0.34–2.31) 0.81 N/A
Tumor Volume >500 vs. ≤500 cm3 1.34 (0.48–3.43) 0.87 N/A 1.12 (0.73–3.15) 0.72 N/A
Tumor Extent Unilobar vs. Bilobar 1.02 (0.38–2.77) 0.96 N/A 1.08 (0.40–2.93) 0.88 N/A
Solitary vs. Multifocal 1.43 (0.61–4.15) 0.76 N/A 1.12 (0.43–2.17) 0.69 N/A
Portal Hypertension Present vs. Absent 2.69 (0.77–9.40) 0.12 N/A 2.53 (0.73–8.80) 0.146 N/A
Encephalopathy Present vs. Absent 1.45 (0.33–6.44) 0.62 N/A 1.38 (0.31–6.05) 1.38 N/A
ECOG PS 0 vs. 1–2 16.17 (2.06–126.83) 0.018 11.29 (1.92–19.06) 0.021 13.01 (1.69–100.4) 0.016 13.52 (1.65–175.27) 0.004
Child Pugh Class A vs. B 8.21 (2.59–26.04) 0.006 6.32 (1.79–16.55) 0.013 7.07 (2.17–23.00) 0.009 12.31 (2.58–59.23) 0.005
Alpha-fetoprotein >400 vs. ≤400 ng/dl 1.12 (0.43–2.97) 0.82 N/A 1.06 (0.40–2.78) 0.911 N/A
Lung Shunt Fraction >10% vs. ≤10% 4.89 (1.55–15.63) 0.004 6.42 (1.96–10.31) 0.029 3.91 (1.33–11.36) 0.013 7.91 (3.06–17.48) 0.011
Treatments prior to Y-90 Yes vs. No 1.67 (0.37–3.18) 0.35 N/A 1.74 (0.51–2.93) 0.41 N/A
Baseline MCS Within 2SD vs. >2SD below of NBS 1.25 (0.22–2.57) 0.38 N/A 1.18 (0.77–3.68) 0.36 N/A
Baseline PCS Within 2SD vs. >2SD below of NBS 1.38 (0.66–3.39) 0.58 N/A 1.29 (0.93–3.17) 0.19 N/A
MCS at 1 month post-Y90 Within 2SD vs. >2SD below of NBS 2.24 (0.98–3.98) 0.17 N/A 2.13 (0.53–3.66) 0.83 N/A
PCS at 1 month post-Y90 Within 2SD vs. >2SD below of NBS 2.59 (1.04–4.23) 0.026 1.73 (1.02–3.18) 0.041 2.03 (1.13–4.57) 0.023 3.28 (1.48–5.13) 0.044
MCS at 3-months post-Y90 Within 2SD vs. >2SD below of NBS 1.87 (0.49–2.13) 0.83 N/A 1.55 (0.90–2.98) 0.88 N/A
PCS at 3 months post-Y90 Within 2SD vs. >2SD below of NBS 1.48 (0.86–3.02) 0.44 N/A 1.47 (0.74–2.93) 0.59 N/A
MCS at 6 months post-Y90 Within 2SD vs. >2SD below of NBS 1.44 (0.82–2.73) 0.23 N/A 1.96 (0.42–4.13) 0.38 N/A
PCS at 6-months post-Y90 Within 2SD vs. >2SD below of NBS 1.59 (0.92–2.11) 0.71 N/A 1.37 (0.79–3.13) 0.62 N/A
  1. Bold data are statistically significant (P <0.05)